Asset profile
Plerixafor
Small molecule
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
64 competitors in this universe: 3 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Plerixafor: this drug | Approved | Small molecule | CXCR4 | ||
| Motixafortide | Approved | Peptide | CXCR4 | ||
| Burixafor (TG-0054) | Phase 2 | Small molecule | CXCR4 | ||
| GPC-100 | Phase 2 | Small molecule | CXCR4 | ||
| AD-214 | Phase 1 | Antibody-derived scaffold | CXCR4 | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Isatuximab | Approved | Monoclonal antibody | CD38 | ||
| Ixazomib | Approved | Small molecule | Proteasome |
…and 49 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(16 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (4)
June 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (3)
May 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (2)
2030 (2)
June 2030 (1)
What to watch
October 2030 (1)
What to watch
2031 (1)
December 2031 (1)
What to watch
2032 (2)
November 2032 (1)
What to watch
December 2032 (1)
What to watch
2034 (1)
December 2034 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.